Christine Sam, MD, discusses strategies for sequencing tucatinib and fam-trastuzumab deruxtecan-nxki in the treatment of patients with HER2-positive breast cancer.
Christine Sam, MD
Advertisement
Articles by Christine Sam, MD
Christine Sam, MD, discusses therapeutic developments in metastatic HER2-positive breast cancer.
Christine Sam, MD, shares strategies to manage interstitial lung disease experienced with fam-trastuzumab deruxtecan-nxki in patients with HER2-positive breast cancer.
Christine Sam, MD, discusses the importance of performing geriatric assessments during the coronavirus disease 2019 pandemic.
Christine Sam, MD, discusses strategies to mitigate the risk of the coronavirus disease 2019 in elderly patients with cancer.
Advertisement
Latest Updated Articles
Dr. Sam on Therapeutic Developments in Metastatic HER2+ Breast CancerPublished: August 12th 2021 | Updated:
Dr. Sam on the Importance of Performing Geriatric Assessments During the COVID-19 PandemicPublished: September 30th 2020 | Updated:
Dr. Sam on Sequencing Tucatinib and Trastuzumab Deruxtecan in HER2+ Breast CancerPublished: August 16th 2021 | Updated:
Dr. Sam on Mitigating Risk of COVID-19 in Elderly Patients With CancerPublished: August 19th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
5